KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Tax Provisions (2016 - 2025)

Travere Therapeutics' Tax Provisions history spans 12 years, with the latest figure at $921000.0 for Q4 2025.

  • For Q4 2025, Tax Provisions rose 1379.17% year-over-year to $921000.0; the TTM value through Dec 2025 reached $988000.0, up 723.33%, while the annual FY2025 figure was $988000.0, 723.33% up from the prior year.
  • Tax Provisions reached $921000.0 in Q4 2025 per TVTX's latest filing, up from $8000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $921000.0 in Q4 2025 to a low of -$84000.0 in Q3 2024.
  • Average Tax Provisions over 5 years is $102650.0, with a median of $52500.0 recorded in 2022.
  • Peak YoY movement for Tax Provisions: surged 1475.0% in 2022, then crashed 800.0% in 2024.
  • A 5-year view of Tax Provisions shows it stood at $4000.0 in 2021, then soared by 1475.0% to $63000.0 in 2022, then increased by 7.94% to $68000.0 in 2023, then plummeted by 205.88% to -$72000.0 in 2024, then surged by 1379.17% to $921000.0 in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Tax Provisions are $921000.0 (Q4 2025), $8000.0 (Q3 2025), and $20000.0 (Q2 2025).